Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Consulting agrmnt
Inv. presentation
|
|
Eloxx Pharmaceuticals, Inc. (ELOX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/29/2021 |
GN
| Eloxx Pharmaceuticals Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis |
| 04/01/2021 |
GN
| Eloxx Pharmaceuticals Acquires Zikani Therapeutics |
| 03/04/2021 |
GN
| Eloxx Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on March 11, 2021 |
| 01/26/2021 |
GN
| Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical Pharmacology in Drug Development |
| 01/20/2021 |
GN
| Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical Pharmacology |
| 01/13/2021 |
GN
| Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation) To Provide Increased Funding and Support for ELX-02 Global Phase 2 Clinical Trial Program |
| 11/18/2020 |
GN
| Eloxx Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference |
| 10/27/2020 |
GN
| Eloxx Announces The Publication of Two Manuscripts on ELX-02 and It's ERSG Library In Two Leading Journals |
| 10/22/2020 |
GN
| Eloxx Presents Two Preclinical Posters at the 2020 North American Cystic Fibrosis Virtual Conference |
| 10/15/2020 |
GN
| Eloxx Pharmaceuticals to Report Third Quarter 2020 Financial Results and Provide Business Update on November 5, 2020 |
| 09/14/2020 |
GN
| Globally Renowned Cystic Fibrosis Expert, Dr. Eitan Kerem, Joins Eloxx Pharmaceuticals as a Senior Consultant |
| 08/26/2020 |
GN
| Eloxx Announces Two Preclinical Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference in October |
| 08/12/2020 |
GN
| Enrollment in the U.S. Phase 2 Clinical Trial in Cystic Fibrosis Has Resumed After Being Paused in Response to the COVID-19 Pandemic |
| 08/06/2020 |
GN
| Eloxx Pharmaceuticals Reports Second Quarter 2020 Financial and Operating Results and Provides Business Update |
| 08/04/2020 |
GN
| Eloxx Pharmaceuticals Receives U.S. Orphan Drug Designation for ELX-02 for the Treatment of Cystic Fibrosis |
| 07/28/2020 |
GN
| Eloxx Pharmaceuticals to Present at the 40th Annual Canaccord Genuity Virtual Growth Conference on August 13th, 2020 |
| 07/21/2020 |
GN
| Eloxx Pharmaceuticals to Report Second Quarter 2020 Financial Results and Provide Business Update on August 6, 2020 |
| 07/15/2020 |
GN
| Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Pharmacology and Experimental Therapeutics |
| 06/17/2020 |
GN
| Enrollment in Phase 2 Clinical Trial in Cystic Fibrosis Has Been Resumed in Israel and Europe After Being Paused Temporarily in Response to the COVID-19 Pandemic |
| 04/13/2020 |
GN
| Eloxx Pharmaceuticals to Report First Quarter 2020 Financial Results and Provide Business Update on May 7, 2020 |
| 03/25/2020 |
GN
| Eloxx Pharmaceuticals Provides Update on the Impact of Novel Coronavirus (COVID-19) on Phase 2 Clinical Trials in Cystic Fibrosis |
| 01/14/2020 |
GN
| Eloxx Pharmaceuticals Provides Update on Progress of Its Phase 2 Clinical Programs for ELX-02 and ERSG Pipeline at Biotech Showcase™ |
| 12/18/2019 |
GN
| Eloxx Pharmaceuticals to Present at the Biotech Showcase™ 2020 on January 14, 2020 |
| 11/18/2019 |
GN
| Eloxx Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference on December 3rd, 2019 |
| 11/07/2019 |
GN
| Eloxx Pharmaceuticals Presents New Positive Data for ELX-02 at the American Society of Nephrology (ASN) Kidney Week 2019 |
| 11/05/2019 |
GN
| Eloxx Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results and Provides Business Update |
| 10/31/2019 |
GN
| Eloxx Pharmaceuticals Presents Positive Data for Lead Investigational Drug, ELX-02, at the North American Cystic Fibrosis Conference (NACFC) |
| 10/10/2019 |
GN
| Eloxx Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Business Update on November 5, 2019 |
| 09/23/2019 |
GN
| Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation) To Provide Funding and Support for ELX-02 U.S. Phase 2 Clinical Trial |
| 09/16/2019 |
GN
| Eloxx Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 3rd, 2019 |
| 09/10/2019 |
GN
| Eloxx Pharmaceuticals to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases on September 24, 2019 |
| 08/26/2019 |
GN
| Eloxx Pharmaceuticals to Participate in the 14th Annual Citi Biotech Conference on September 5th, 2019 |
| 08/13/2019 |
GN
| Eloxx Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Society of Nephrology (ASN) Kidney Week 2019 |
| 08/07/2019 |
GN
| Eloxx Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results and Provides Business Update |
|
|
|